Composition for preventing or treating caries

By developing a peptide composed of 10 amino acids for caries treatment, the problems of tooth regeneration and pulp protection in caries treatment have been solved, and the regeneration and inflammation of dentin and pulp are reduced, which has improved caries The effect of treatment.

CN118973598APending Publication Date: 2024-11-15HYSENSBIO CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380025418.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-03-08
Filing Date
2023-01-06
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing caries treatment methods have the problem of pulp necrosis due to fear delayed treatment period and fine leakage of dental materials, which makes it difficult to effectively protect teeth and promote pulp regeneration.

Method used

A peptide composed of 10 amino acids was developed to promote the regeneration of dentin or pulp tissue, increase the expression of Dspp, Dmp1 and Nestin genes, form dentin-dump-like tissue, reduce the expression of inflammatory factors, and protect teeth. Myeloid cells and activate to dentin cells.

Benefits of technology

Effectively improve or treat caries, increase the healing ability of the pulp, reduce irreversible pain, promote dentin regeneration, protect the pulp, and reduce inflammatory response.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118973598A_ABST
    Figure CN118973598A_ABST
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating caries and a use thereof, the pharmaceutical composition according to the present invention comprising, as an active ingredient, a peptide comprising the amino acid sequence of general formula 1. K-Y-R1-R2-R3-R4-R5-R6-R7-R8 (general formula 1), wherein in the general formula 1, R1 is arginine (R), lysine (K) or glutamine (Q); r2 is arginine (R) or glutamine (Q); r3, R4 and R5 are respectively arginine (R) or lysine (K); r6 is asparagine (N) or serine (S); and R7 and R8 are lysine (K) or tyrosine (Y).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a pharmaceutical composition, and more particularly, to a pharmaceutical composition for preventing or treating dental caries without removing infected tooth substance. Background Art

[0002] Dental caries is one of the most common chronic diseases, with 3.5 billion people reportedly suffering from it worldwide (Dye 2017; Kassebaum et al. 2015; World Health Organization 2017). According to a 2013 survey by the Ministry of Health and Welfare of South Korea, the dental caries experience rate of adult males is about 87%, and that of females is about 90%, showing a high incidence rate. With the development of overall medical technology, the average life expectancy of the people has been extended. In order to improve the quality of life, the importance of oral health management has increased, and the importance of preserving natural teeth has been emphasized. Although dental caries has no symptoms in the early stage, it will induce various pains as the disease progresses, and eventually the teeth will be lost. The final edentulous state will lead to eating disorders, which will become a serious factor hindering the overall quality of life (Bortoluzzi et al. 2012).

[0003] Normally, damage to dentin caused by non-infectious reasons simply requires a repair process for the lost dentin, but in the case of caries, the impact of bacteria that cause the affected dentin and infection should be minimized, which is different from the treatment of other non-infectious dentin diseases. Caries, unlike other dentin-endodontic diseases, begins with infection of the dentin caused by the pathogenic bacteria of caries. Since caries is an infectious disease caused by bacteria, it is important to minimize the impact of bacteria by removing the affected dentin. Therefore, the treatment of caries in the past usually applies a treatment method that removes the infected dentin, physically removes the bacterial infection source, and repairs the removed dentin area.

[0004] The current treatment methods for common dental caries have problems such as delaying treatment due to fear of dental treatment, and problems caused by the use of artificial dental materials.

[0005] Teeth are composed of enamel, dentin, cementum as hard tissues and pulp as soft tissue inside. The nerves and blood vessels of the pulp are well developed, and the odontoblasts that form the dentin are located at the boundary between the pulp and the dentin. Considering whether the structure that constitutes the tooth is eroded or not, caries can be divided into five stages according to the degree of development. Specifically, the first stage of caries is limited to the enamel with slight damage but almost no subjective symptoms, the second stage is accompanied by damage near the boundary between the enamel and dentin and symptoms of sensitive teeth, the third stage is the stage where the dentin is affected and the dentin is damaged and pain can be felt by external stimulation, the fourth stage is the stage where the pulp is affected and inflammation occurs even without external stimulation, and the fifth stage is the stage where the pulp is necrotic and severe pain is accompanied. Generally, caries is often felt in the second and third stages corresponding to the initial stage. The second and third stages are suitable for treating caries, and the influence of caries pathogens can be minimized.

[0006] It is known that even if dental treatment can be quickly received based on subjective symptoms, the appropriate treatment stage is often missed, which is attributed to the traditional treatment method of caries. The current treatment of caries is achieved by mechanically removing the weakened tooth substance and filling it with new materials. Most dental patients tend to delay the treatment period due to anxiety, worry, fear and tension about dental treatment. As a result, the appropriate treatment period is missed, and a considerable part of the tooth substance needs to be removed during the treatment process. Anxiety or worry about the treatment of caries is manifested in various age groups, from children to the elderly. It is known that the fear of dental treatment is particularly great in the case of young children and adolescents (0 to 14 years old) who are not yet mentally and physically mature. In 1984, Berggren and Meynert investigated the reasons for avoiding dental treatment among adults aged 20 to 40 and reported that about 85% of the subjects had a fear of dental treatment due to terrible dental treatment experiences in childhood. In particular, the formation of cavities in teeth or the pain experienced during anesthesia or tooth extraction were pointed out as the main reasons for fear of dental treatment. Fear of dental treatment developed in childhood may persist into adulthood and may therefore be a factor in missing the right time for treatment.

[0007] In the past, dental materials used for the treatment of caries have been used to restore the structure and function of teeth from tooth damage, and to use restoration materials for preservation and repair formed of various components such as amalgam, glass ionomer cement, composite resin, gold, and ceramics. As for the restoration materials used in dental treatment so far, there is a high possibility of micro leakage in the long term, so chemical stimulation and micro leakage of dental materials used for preservation and repair of teeth may cause or worsen the pathological changes of the dental pulp. Therefore, the development of inflammatory reaction leads to necrosis of the dental pulp, and the loss of tooth substance due to root canal treatment and additional tooth removal of the dental pulp. According to reports, dental root caries, which is common in the elderly, is difficult to prevent moisture, ensure vision, and approach during repair. The edge of the cavity is located in the cementum and dentin, so the root caries is different from the caries in the enamel, and the resistance to acid corrosion is weak. Due to the incomplete edge, the recurrence of caries is very common. Furthermore, since the restoration is located in a position where it is difficult to maintain its shape, the restoration is prone to fall off, and the thickness of the dentine from the root to the pulp is not thick, resulting in a high frequency of pain after treatment. When removing caries, the pulp is easily exposed, resulting in many cases of excessive root canal treatment, making it difficult to preserve the natural tooth.

[0008] In the early stages of caries, you may feel little or no pain. Since caries has not progressed to the pulp of the tooth, which has nerves and blood vessels, only the infected part is removed and filled with dental materials. However, when caries invades the pulp, root canal treatment, which is generally called nerve treatment, is required. Root canal treatment is a treatment that removes all nerve and blood vessel tissues in the pulp and fills them with dental materials. After the root canal treatment is completed, the removed part of the tooth is filled with dental materials. A tooth that has undergone root canal treatment is prone to chipping if it is only filled, so a gold crown made of cast metal is placed after the filling treatment. If caries continues to progress to the pulp for a long time, a pus pocket will form in the bone at the end of the root of the tooth, and the pus will flow through the bone to the gums. In this case, it can also be treated with root canal treatment, but if the pus pocket in the bone is too large, it will be necessary to perform surgery to remove the pus pocket or extract the tooth. In root canal treatment, which removes pulp cells instead of protecting them, you will not feel the chewing sensation of a natural tooth, but only feel the inconvenience of a foreign body sensation. In relation to the immune response in teeth, it is known that the autophagy of odontoblasts is related to the differentiation of new odontoblasts, cell survival rate, and protection from cell death. From the perspective of protection and adaptation of odontoblasts, the autophagy of odontoblasts is expected to have a beneficial effect on the survival of pulp cells and new odontoblasts. However, according to conventional root canal treatment methods, only odontoblasts can be removed, so it is difficult to expect a beneficial effect from odontoblasts.

[0009] In this context, the present inventors have worked tirelessly to develop a more effective preparation for treating dental pulp caries. As a result, they have developed a new use of a peptide for promoting the regeneration of dentin or pulp tissue for preventing, improving or treating dental caries, and have completed the present invention. Summary of the invention

[0010] Technical issues

[0011] The object of the present invention is to provide a method for improving or treating dental caries and the pain caused by the dental caries, wherein the dental caries include dental caries of tooth roots, dental caries of young teeth that are about to fall out, and dental caries of erupting teeth.

[0012] Another object of the present invention is to provide an improvement or treatment effect for caries, increase the healing ability of dental pulp damaged by caries and reduce the expression of inflammatory factors so as to prevent the disease from developing into irreversible pain.

[0013] Another object of the present invention is to provide a method for improving or treating dental caries, which is achieved by increasing the autophagocytic function of odontoblasts, protecting the dental pulp and reactivating odontoblasts in an environment where the dental pulp is damaged by dental caries.

[0014] The objects of the present invention are not limited to the above-mentioned contents, and a person having ordinary knowledge in the technical field to which the present invention belongs can clearly understand other objects not mentioned from the following description.

[0015] Solution to the problem

[0016] The present inventors have developed a preparation for preventing, improving and treating dental caries, comprising a peptide consisting of 10 amino acids, and its use.

[0017] It was confirmed that the peptide can increase the expression levels of Dspp, Dmp1 and Nestin genes, which are marker genes for odontoblast differentiation, and exhibits an effect of promoting dentin regeneration, while not showing any cytotoxicity to cells of dental pulp tissue.

[0018] Furthermore, it was confirmed that the peptide forms a dentin-pulp-like tissue having a morphology most similar to that of a dentin-pulp tissue in vivo, increases the level of collagen formation, and increases the expression level of DSP, an odontoblast-specific differentiation marker gene.

[0019] As one embodiment for achieving the above object, the present invention provides a pharmaceutical composition for treating dental caries, which comprises a peptide formed by an amino acid sequence of the following general formula 1.

[0020] KY-R1-R2-R3-R4-R5-R6-R7-R8 (Formula 1)

[0021] In the general formula 1,

[0022] R1 is arginine R, lysine K or glutamine Q;

[0023] R2 is arginine R or glutamine Q;

[0024] R3, R4 and R5 are arginine R or lysine K respectively;

[0025] R6 is asparagine N or serine S; and

[0026] R7 and R8 are lysine K or tyrosine Y.

[0027] The term "dentine" of the present invention is also referred to as "dentin", and refers to a slightly yellowish white hard tissue that forms the majority of teeth. The dentin is covered by enamel in the crown of the tooth and by cementum in the root of the tooth, and therefore is not exposed on the tooth surface. However, as the enamel wears away with age, the dentin will be exposed at the front end of the crown or the occlusal surface. Although the dentin is a bone tissue, the main body of the cells that form the dentin is located in the pulp, and only their protrusions extend into the dentin, which is different from ordinary bone tissue.

[0028] The term "dental pulp" of the present invention is also called "dental pulp", which refers to the soft connective tissue that fills the pulp cavity inside the tooth. Anatomically, it can also refer to a region where nerves and blood vessels are richly distributed and reach the inner surface of the dentin.

[0029] The peptides contained in the preparation provided in the present invention not only show no cytotoxicity, but also can increase the expression levels of Dspp, Dmp1 and Nestin genes which are marker genes for odontoblast differentiation. When transplanted into a living body together with dental pulp tissue cells, the dental pulp tissue cells can show the characteristics of forming dentin / pulp tissue-like tissue.

[0030] As long as the peptide contained in the preparation provided by the present invention can show dental caries therapeutic effects, even mutant peptides whose amino acid sequence and one or more amino acid residues constituting the peptide have different sequences are also included in the category of the peptide provided by the present invention.

[0031] Generally, it is known in the art to which the present invention belongs that amino acid exchanges in proteins and polypeptides do not change the activity of the molecule as a whole. The most common exchanges are exchanges between amino acid residues Ala / Ser, Val / Ile, Asp / Glu, Thr / Ser, Ala / Gly, Ala / Thr, Ser / Asn, Ala / Val, Ser / Gly, Thy / Phe, Ala / Pro, Lys / Arg, Asp / Asn, Leu / Ile, Leu / Val, Ala / Glu, Asp / Gly. In addition, peptides that increase the structural stability of the peptide related to heat, pH, etc. or increase the regeneration promoting ability of dentin or pulp tissue can be included through mutations or modifications in the amino acid sequence.

[0032] For example, even if glutamine, which is the acidic amino acid at No. 3 of the peptide of sequence number 1 provided in the present invention, is replaced by lysine or arginine, which is a basic amino acid, the effect of the peptide provided in the present invention can be directly expressed; even if arginine, which is the basic amino acid at No. 4 or 5 of the peptide of sequence number 1, is replaced by glutamine, which is an acidic amino acid, or lysine, which is a basic amino acid, the effect of the peptide provided in the present invention can be directly expressed; even if lysine, which is the basic amino acid at No. 6, 7 or 9 of the peptide of sequence number 1, is replaced by arginine, which is a basic amino acid, or tyrosine, which is an aromatic amino acid, the effect of the peptide provided in the present invention can be directly expressed; even if asparagine, which is the acidic amino acid at No. 8 of the peptide of sequence number 1, is replaced by serine, which is a neutral amino acid, the effect of the peptide provided in the present invention can be directly expressed; even if tyrosine, which is the aromatic amino acid at No. 10 of the peptide of sequence number 1, is replaced by lysine, which is a basic amino acid, the effect of the peptide provided in the present invention can be directly expressed.

[0033] As described above, even if the acidic amino acids, basic amino acids or aromatic amino acids constituting the peptide of the present invention are replaced by different acidic amino acids, basic amino acids, neutral amino acids or aromatic amino acids, respectively, the effects of the peptide provided in the present invention can be directly exhibited. Therefore, mutant peptides in which the amino acid sequence of the peptide of the present invention and one or more amino acid residues have different sequences also fall within the scope of the peptides provided in the present invention.

[0034] Furthermore, even if the peptide contained in the preparation of the present invention has a form in which any amino acid is added to its N-terminus or C-terminus, it can directly express the effect of the peptide provided in the present invention, and therefore, it is included in the category of the peptide provided in the present invention. As one example, it can be a form in which 1 to 300 amino acids are added to the N-terminus or C-terminus of the peptide, as another example, it can be a form in which 1 to 100 amino acids are added to the N-terminus or C-terminus of the peptide, and as another example, it can be a form in which 1 to 24 amino acids are added to the N-terminus or C-terminus of the peptide.

[0035] Regarding the 96 peptides corresponding to the general formula 1 provided in the present invention, the mRNA level of the Dspp gene, which is a marker of odontoblast differentiation, was significantly increased in the MDPC-23 cells treated with the 96 peptides, compared with the mRNA level of the Dspp gene measured in the MDPC-23 cells not treated with the peptides (control group).

[0036] According to reports so far, it is known that when the mRNA expression level of DSPP increases, it promotes odontoblast differentiation and dentin regeneration. Therefore, it can be seen that the 96 peptides that show the effect of increasing the mRNA level of the Dspp gene can show the effect of promoting odontoblast differentiation and dentin regeneration (Taduru Sreenath et al., THE JOURNAL OF BIOLOGICAL CHEMISTRY, Vol. 278, No. 27, Issue of July 4, pp. 24874-24880, 2003; William T. Butler et al, Connective Tissue Research, 44 (Suppl. 1): 171-178, 2003).

[0037] As another embodiment, the present invention provides a polynucleotide encoding the peptide.

[0038] For the polynucleotide, one or more bases may be mutated by substitution, deletion, insertion or a combination thereof. In the case of preparing by chemically synthesizing a nucleotide sequence, a synthesis method known in the art to which the present invention belongs may be used, such as the method described in the literature (Engels and Uhlmann, Angew Chem Int Ed Engl., 37: 73-127, 1988), and it may be synthesized using triester, phosphite, phosphoramidite and H-phosphate methods, polymerase chain reaction (PCR) and other automatic primer methods, oligonucleotide synthesis on a solid support, etc. For example, a polynucleotide encoding a peptide of the present invention may include the base sequence of sequence number 4.

[0039] As another embodiment, the present invention provides an expression vector comprising the polynucleotide, a transformant comprising the expression vector, and a method for preparing the peptide using the transformant.

[0040] The term "expression vector" of the present invention refers to a recombinant vector that can express a target peptide in a target host cell, and means a gene construct that contains necessary regulatory elements that are operably linked to express a gene insert. The expression vector contains expression regulatory elements such as a start codon, a stop codon, a promoter, and an operator gene. The start codon and the stop codon are usually considered to be part of the nucleotide sequence encoding the polypeptide, and must exhibit an effect in an individual when the gene construct is administered, and must be in frame with the coding sequence. The promoter of the vector can be constitutive or inducible.

[0041] The term "operably linked" of the present invention refers to a state in which a nucleic acid expression regulatory sequence and a nucleic acid sequence encoding a target protein or RNA are functionally linked in order to perform a common function. For example, operably linking a promoter to a nucleic acid sequence encoding a protein or ribonucleic acid can affect the expression of the coding sequence. Operable linkage with an expression vector can be prepared using gene recombination techniques known in the art to which the present invention belongs, and site-specific DNA cleavage and ligation can use enzymes commonly known in the art to which the present invention belongs.

[0042] In addition, in order to promote the separation of peptides from the cell culture fluid, the expression vector may include a signal sequence for discharging the peptides. Specific initiation signals may also be required when performing effective translation of the inserted nucleotide sequence. These signals include the ATG initiation codon and adjacent sequences. In some cases, an exogenous translation regulation signal that may include the ATG initiation codon may be provided. These exogenous translation regulation signals and initiation codons may be a variety of natural and synthetic sources. Expression efficiency may be increased by introducing appropriate transcription or translation enhancers.

[0043] Furthermore, in order to easily detect the peptide, the expression vector may further comprise a protein tag that can be optionally removed using an endopeptidase.

[0044] The term "tag" of the present invention refers to a molecule that exhibits an activity or characteristic that can be quantified, and may be a fluorescent molecule including a chemical fluorescent substance (fluoracer) (such as fluorescein) and a polypeptide fluorescent substance (such as fluorescent protein (GFP) or related proteins); or an epitope tag such as a Myc tag, a Flag tag, a histidine tag, a leucine tag, an IgG tag, a streptavidin tag, etc. In particular, when an epitope tag is used, a peptide tag consisting of 6 or more amino acid residues may be preferably used, and a peptide tag consisting of 8 to 50 amino acid residues may be more preferably used.

[0045] In the present invention, the expression vector may comprise a nucleotide sequence encoding the peptide of the present invention, wherein the peptide is a peptide for promoting the regeneration of dentin or pulp tissue and for treating dentin hypersensitivity. The vector used in this case may preferably be a plasmid DNA, a phage DNA, etc., and more preferably may be a commercially developed plasmid (pUC18, pBAD, pIDTSAMRT-AMP, etc.), an Escherichia coli-derived plasmid (pYG601 BR322, pBR325, pUC118, pUC119, etc.), a Bacillus subtilis-derived plasmid (pUB110, pTP5, etc.), a yeast-derived plasmid (YEp13, YEp24, YCp50, etc.), a phage DNA (Charon4A, Charon21A, EMBL3, EMBL4, λgt10, λgt11, λZAP, etc.), an animal virus vector (retrovirus, adenovirus, vaccinia virus, etc.) virus, etc.), insect virus vectors (baculovirus, etc.), but are not particularly limited thereto as long as the peptide can be produced. The expression vector exhibits different protein expression amounts and modifications depending on the host cell, so it is preferred to select and use the host cell that best suits the purpose.

[0046] The expression vector provided in the present invention can be introduced into the host for transformation, so that the transformant provided in the present invention can be prepared, and the polynucleotide contained in the expression vector is expressed to be used for the production of the peptide. The transformation can be carried out by a variety of methods, such as the CaCl2 precipitation method, the Hanahan method in which a reducing substance called dimethyl sulfoxide (DMSO (dimethyl sulfoxide)) is used to improve the efficiency in the CaCl2 precipitation method, electroporation, calcium phosphate precipitation, protoplast fusion, stirring method using silicon carbide fiber, Agrobacterium-mediated transformation method, transformation method using polyethylene glycol (PEG), dextran sulfate, liposome and drying / inhibition-mediated transformation method, etc., but as long as the peptide can be produced, it is not particularly limited thereto. Furthermore, the host used in preparing the transformant is not particularly limited as long as it can produce the peptide, but may be bacterial cells, such as Escherichia coli, Streptomyces, Salmonella typhimurium, etc.; yeast cells, such as Saccharomyces cerevisiae, Schizosaccharomyces pombe, etc.; fungal cells, such as Pichia pastoris, etc.; insect cells, such as Drosophila, Spodoptera Sf9 cells, etc.; animal cells, such as CHO cells, COS cells, NSO cells, 293 cells, human melanoma cells, etc.; or plant cells.

[0047] The transformant can also be used in a method for producing the peptide of the present invention, wherein the peptide is a peptide for promoting the regeneration of dentin or pulp tissue and for treating dentin hypersensitivity. Specifically, the method for producing the peptide for promoting the regeneration of dentin or pulp tissue and for treating dentin hypersensitivity of the present invention may include: step (a), obtaining a culture by culturing the transformant; and step (b), recovering the peptide of the present invention from the culture.

[0048] The term "culture" of the present invention refers to a method of growing and developing microorganisms under appropriately artificially adjusted environmental conditions. In the present invention, the method of culturing the transformant can be carried out using methods known in the technical field to which the present invention belongs. Specifically, with regard to the culture, continuous culture can be carried out in a batch process or a fed batch or a repeated fed batch process (fed batch or repeated fed batch process), but as long as it can be produced by expressing the peptide of the present invention for promoting the regeneration of dentin or pulp tissue and for treating dentin hypersensitivity, it is not particularly limited to this.

[0049] The culture medium used for the culture needs to be a conventional culture medium containing an appropriate carbon source, nitrogen source, amino acid, vitamin, etc., under aerobic conditions, and the temperature, pH, etc., and the conditions of the specific strain need to be adjusted in an appropriate manner. As a usable carbon source, a mixed sugar of glucose and xylose is used as the main carbon source, in addition to: sugars and carbohydrates such as sucrose, lactose, fructose, maltose, starch, cellulose; and oils and fats such as soybean oil, sunflower oil, castor oil, coconut oil, etc.; and fatty acids such as palmitic acid, stearic acid, linoleic acid; and alcohols such as glycerol, ethanol; and organic acids such as acetic acid. These substances can be used individually or as a mixture. As usable nitrogen sources, inorganic nitrogen sources such as ammonia, ammonium sulfate, ammonium chloride, ammonium acetate, ammonium phosphate, ammonium carbonate and ammonium nitrate can be used; amino acids such as glutamic acid, methionine, glutamine; and organic nitrogen sources such as peptone, NZ-amine, meat extract, yeast extract, malt extract, corn steep liquor, casein hydrolyzate, fish or its decomposition products, defatted soybean cake or its decomposition products, etc. can be used. These nitrogen sources can be used alone or in combination. In the culture medium, as a phosphorus source, monopotassium phosphate, dipotassium phosphate and corresponding sodium salts can be included. As usable phosphorus sources, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or corresponding sodium salts are included. And as inorganic compounds, sodium chloride, calcium chloride, ferric chloride, magnesium sulfate, ferric sulfate, manganese sulfate and calcium carbonate can be used. Finally, growth essential substances such as amino acids and vitamins can be added to the substance for use.

[0050] In addition, appropriate precursors can be used in the culture medium. The raw materials can be added to the culture in a batch, fed-batch or continuous manner during the culture process, but are not particularly limited thereto. The pH of the culture can be adjusted by using alkaline compounds such as sodium hydroxide, potassium hydroxide, ammonia, etc.; acidic compounds such as phosphoric acid or sulfuric acid, etc. in an appropriate manner.

[0051] Furthermore, the generation of bubbles can be suppressed by using a defoaming agent such as fatty acid polyethylene glycol ester. In order to maintain an aerobic state, oxygen or an oxygen-containing gas (e.g., air) is injected into the culture. The temperature of the culture is usually 27° C. to 37° C., preferably 30° C. to 35° C. The culture is continued until the production amount of the peptide reaches a maximum value. This purpose can usually be achieved within 10 to 100 hours.

[0052] Furthermore, the step of recovering the peptide from the culture may be performed by a method known in the art to which the present invention belongs. Specifically, the recovery method is not particularly limited as long as it is applicable to the recovery of the produced peptide, and preferably, centrifugation, filtration, extraction, spraying, drying, evaporation, precipitation, crystallization, electrophoresis, fractional dissolution (e.g., ammonium sulfate precipitation), chromatography (e.g., ion exchange, affinity, hydrophobicity, and size exclusion) and the like can be used.

[0053] The pharmaceutical composition of the present invention can promote the formation of dentin / pulp tissue-like tissue by pulp tissue cells, and can be used to treat caries according to the method of repairing dentin or pulp tissue.

[0054] The peptide contained in the pharmaceutical composition can be used in the form of a single peptide, can be used in a form in which the peptide is repeatedly linked two or more times, and can also be used in the form of a complex in which a drug that exhibits antibacterial effects on dental caries pathogens is bound to the N-terminus or C-terminus of the peptide.

[0055] The term "caries" of the present invention may refer to an infectious disease caused by bacteria inhabiting the surface of teeth.

[0056] The term "prevention" of the present invention means all actions to inhibit or delay the occurrence of dental caries by administering a pharmaceutical composition for preventing or treating dental caries comprising the peptide of the present invention.

[0057] The term "treatment" of the present invention refers to all actions of treating caries by promoting the regeneration of dentin or pulp tissue by administering a pharmaceutical composition comprising the peptide of the present invention as an active ingredient to an individual in need of caries treatment.

[0058] The pharmaceutical composition of the present invention can be prepared into a pharmaceutical composition for treating caries in which the peptide further contains an appropriate carrier (natural or non-natural carrier), excipient or diluent commonly used in the preparation of the pharmaceutical composition. Specifically, the pharmaceutical composition can be formulated into a sterile injection that can be administered to the site of caries induction according to the usual method. In the present invention, the carrier, excipient and diluent that can be contained in the pharmaceutical composition can be exemplified by lactose, glucose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, collagen, etc. When the peptide of the present invention is formulated, it can be prepared using commonly used diluents or excipients such as fillers, brighteners, binders, wetting agents, disintegrants, surfactants, etc. In particular, it may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried agents, suppositories, ointments (e.g., endodontic transplant materials, etc.), etc. As non-aqueous solvents and suspensions, vegetable oils such as propylene glycol, polyethylene glycol, olive oil, etc., and injectable esters such as ethyl oleate, etc. can be used. As the base of the suppository, synthetic fatty acid esters (witepsol), polyethylene glycol, Tween 61, cocoa butter, lauric acid glyceride fat, glycerin gelatin, etc. can be used.

[0059] The content of the peptide contained in the pharmaceutical composition of the present invention is not particularly limited, but based on the total weight of the final composition, the peptide may be contained in an amount of 0.0001 to 50 wt %, more preferably 0.01 to 20 wt %.

[0060] The pharmaceutical composition of the present invention can be administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" of the present invention refers to an amount sufficient for the treatment or prevention of a disease at a reasonable benefit / risk ratio that can be applied to medical treatment or prevention. The effective dosage level can be determined based on the severity of the disease, the activity of the drug, the patient's age, weight, health, gender, the patient's sensitivity to the drug, the administration time, administration route and excretion rate of the composition of the present invention used during treatment, the elements of the drugs used in combination with or containing the composition of the present invention used, and other elements known in the medical field. The pharmaceutical composition of the present invention can be administered independently or in combination with a known pharmaceutical composition for treating dental caries. It is important to take all the above factors into consideration and administer the drug in an amount that has no side effects and can achieve the maximum effect with the minimum amount.

[0061] A person skilled in the art of the present invention may determine the dosage of the pharmaceutical composition of the present invention by considering the purpose of use, the degree of disease poisoning, the age, weight, sex, previous illness of the patient, or the type of substance used as an active ingredient. For example, each adult may be administered about 0.1 ng to about 100 mg / kg of the pharmaceutical composition of the present invention, preferably, it can be administered at 1 ng to about 10 mg / kg, and the administration frequency of the composition of the present invention is not particularly limited thereto, but may be administered once a day or divided into doses for multiple administrations. The dosage does not limit the scope of the present invention in any aspect.

[0062] As still another embodiment, the present invention provides a method for treating dental caries, comprising the step of administering the pharmaceutical composition in a pharmaceutically effective amount to an individual other than a person suffering from dental caries.

[0063] The term "subject" of the present invention refers to mammals including mice, livestock, etc. that need to be treated for dental diseases without limitation, but excludes humans among subjects who develop the disease.

[0064] The pharmaceutical composition for treating dental caries of the present invention can be administered by any general route as long as it can reach the target tissue. The pharmaceutical composition of the present invention is not particularly limited thereto, but can be administered by routes such as oral administration or oral injection according to the purpose.

[0065] As another embodiment, the present invention provides a quasi-drug composition for preventing or improving dental caries, comprising the peptide.

[0066] The term "improvement" according to the present invention refers to all actions that at least reduce a parameter associated with the state being treated, for example, the extent of a symptom.

[0067] In the present invention, the improvement can be explained as follows: administering a pharmaceutical composition containing the peptide of the present invention as an active ingredient to an individual in need of dental caries treatment to promote the regeneration of dentin or pulp tissue, thereby improving or beneficially changing the symptoms of dental caries.

[0068] The term "quasi-drug" in the present invention refers to items used for the purpose of diagnosing, treating, improving, alleviating, treating or preventing diseases in humans or animals, and whose effects are milder than those of drugs. For example, according to the Pharmaceutical Affairs Law, quasi-drugs refer to items other than those used as drugs, including fiber / rubber products used to treat or prevent human / animal diseases, items that are not instruments or machines and similar items that have slight or no direct effects on the human body, sterilizers / insecticides used to prevent infectious diseases, etc.

[0069] In the present invention, the type and dosage form of the quasi-drug composition containing the peptide are not particularly limited, and may be, for example, an oral disinfectant cleanser, an oral hygiene product, a toothpaste, a dental floss, an oral ointment, or the like.

[0070] As another embodiment, the present invention provides a health functional food composition for preventing or improving dental caries, comprising the peptide.

[0071] The term "food" of the present invention includes meat, sausage, bread, chocolate, candy, fast food, biscuits, pizza, instant noodles, other noodles, chewing gum, dairy products including ice cream, various soups, beverages, tea, rehydration, alcoholic beverages, vitamin complexes, health functional foods and health foods, etc., including all foods in the conventional sense.

[0072] The functional food is a term identical to food for special health use (FoSHU), and refers to a food with high medical and medical effects that is processed to effectively present the regulating function of the organism in addition to providing nutrition. Among them, the so-called "function" refers to regulating nutrients (to the structure and function of the human body) or obtaining useful effects in health care purposes (such as physiological effects, etc.). The food of the present invention can be prepared by the method commonly used in the technical field to which the present invention belongs, and the raw materials and ingredients that are usually added can be added to prepare it during the preparation. In addition, as for the dosage form of the food, as long as it is a dosage form that can be identified as food, it can be prepared without restriction. The food composition of the present invention has the following advantages: it can be prepared into a variety of dosage forms, and unlike ordinary medicines, food can be used as a raw material, so there are no side effects that may occur when taking medicines for a long time, and it is excellent in portability, so the food of the present invention can be taken as an auxiliary agent to enhance the effect of preventing or improving dental caries.

[0073] The health food refers to a food that has a positive effect of maintaining or improving health compared to ordinary food, and the health supplement food refers to a food for health supplement purposes. Depending on the situation, the terms health functional food, health food, and health supplement food can be used interchangeably.

[0074] Specifically, the health functional food refers to the peptide of the present invention added to food materials such as beverages, teas, spices, chewing gums, biscuits, etc., or as a food prepared by encapsulation, powderization, suspension, etc., which brings specific effects on health when ingested. However, unlike ordinary medicines, since food is used as a raw material, it has the advantage of not causing side effects when taking medicines for a long time.

[0075] The food composition of the present invention can be ingested daily, and thus can be expected to have a good effect on preventing or improving dental caries, and thus can be used very effectively.

[0076] The food composition may further include a physiologically acceptable carrier. The type of the carrier is not particularly limited, and any carrier commonly used in the technical field to which the present invention belongs may be used.

[0077] Furthermore, the food composition may include additives that can be commonly used in food compositions to improve smell, taste, vision, etc. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folic acid, pantothenic acid, etc. may be included. Furthermore, minerals such as zinc (Zn), iron (Fe), calcium (Ca), magnesium (Mg), manganese (Mn), copper (Cu), chromium (Cr), etc. may be included. Furthermore, amino acids such as lysine, tryptophan, cysteine, valine, etc. may be included.

[0078] In addition, the food composition may include food additives, such as preservatives (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate, etc.), bactericides (bleaching powder and high-efficiency bleaching powder, sodium hypochlorite, etc.), antioxidants (butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), etc.), colorants (tar pigments, etc.), colorants (sodium nitrite, sodium acetate, etc.), bleaching agents (sodium sulfite), seasonings (MSG sodium glutamate, etc.), sweeteners (sweetness, cyclamates, saccharin, sodium, etc.), spices (vanillin, lactones, etc.), expanders (alum, D-potassium hydrogen tartrate, etc.), enhancers, emulsifiers, thickeners (paste), film-forming agents, glue bases, foam inhibitors, solvents, improvers, etc. The additives may be selected and used in appropriate amounts according to the type of food.

[0079] Peptide of the present invention can be directly added or used together with other foods or food ingredients, and can be suitably used according to conventional methods.Can suitably determine the mixed amount of active ingredient according to its purpose of use (prevention, health or therapeutic treatment).Usually, when preparing food or beverage, relative to food or beverage, food composition of the present invention can add below 50 weight portions, specifically, can add the amount below 20 weight portions.But, in the case of long-term intake for the purpose of health and hygiene, can comprise the amount below the above described scope, owing to there is no problem aspect safety, can also use the amount above the described scope as active ingredient.

[0080] As an example of the food composition of the present invention, it can be used as a health drink composition. In the case, it can contain a variety of flavoring agents or natural carbohydrates as added ingredients, just like general beverages. The natural carbohydrates can be monosaccharides, such as glucose and fructose; disaccharides, such as maltose and sucrose; polysaccharides, such as dextrin and cyclodextrin; sugar alcohols, such as xylitol, sorbitol, erythritol, etc. Sweeteners can use natural sweeteners, such as thaumatin and stevia extract; synthetic sweeteners, such as saccharin and aspartame, etc. The ratio of the natural carbohydrates in each 100 mL of the health drink composition of the present invention can generally be about 0.01g to 0.04g, specifically about 0.02g to 0.03g.

[0081] In addition to the above, the health drink composition can include multiple nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectin, pectate, alginic acid, alginate, organic acid, protective colloid thickener, pH adjusting agent, stabilizer, preservative, glycerine, ethanol or carbonating agent etc. In addition, the pulp for preparing natural fruit juice, fruit juice beverage or vegetable beverage can also be included. This composition can be used independently or in combination. Although the ratio of this additive is not particularly important, in the health drink composition of the present invention of every 100 weight portions, select in the scope of 0.01 to 0.1 weight portion usually.

[0082] If the food composition of the present invention can show the effect of preventing or improving dental caries, the peptide of the present invention can be included in various weight %, specifically, based on the gross weight of the food composition, it can include 0.00001 to 100 weight % or 0.01 to 80 weight % of the peptide of the present invention, but is not limited to this.

[0083] Effects of the Invention

[0084] The present invention can provide a use for improving or treating dental caries and pain caused by the dental caries, wherein the dental caries include dental caries of tooth roots, dental caries of young teeth that are about to fall out, and dental caries of erupting teeth.

[0085] Another object of the present invention is to provide an improvement or treatment effect for caries, increase the healing ability of dental pulp damaged by caries and reduce the expression of inflammatory factors so as to prevent the disease from developing into irreversible pain.

[0086] The present invention can provide a method for improving or treating dental caries, which is achieved by increasing the autophagocytic function of odontoblasts, protecting the dental pulp and reactivating the odontoblasts in an environment where the dental pulp is damaged by dental caries.

[0087] The effects of the present invention are not limited to the above-mentioned contents, and a person having ordinary knowledge in the technical field to which the present invention belongs can clearly understand other effects not mentioned from the following description. BRIEF DESCRIPTION OF THE DRAWINGS

[0088] Figure 1a and Figure 1b The results of observing the permeability and stability of the peptide (SEQ ID NO: 96) contained in the pharmaceutical composition according to the embodiment of the present invention in various caries environments are shown in FIG. Figure 1a The results are as follows: teeth extracted from humans and showing a stage 2 to 3 of dentine caries were coated with a peptide bonded with rhodamine, a fluorescent dye, and fixed with 4% paraformaldehyde about one minute later. The teeth were cut into sections with a thickness of 0.1 mm in the sagittal direction using a digital low-speed diamond cutter and observed under a confocal microscope. Figure 1b These are the results of confirming the stability of the peptide in the pharmaceutical composition in the presence of S. mutans, a dental caries pathogen, by MALDI-TOF analysis.

[0089] Figure 2a are the results of treating the pharmaceutical composition according to the embodiments of the present invention in the caries rat model according to the various stages of caries, Figure 2b These are the results of comparing the number of inflammatory cells when the pharmaceutical composition according to the examples of the present invention was treated on teeth suffering from caries in a caries rat model.

[0090] Figure 3 The chart is a cell experiment simulating pulp inflammation caused by caries corresponding to stage 4, showing the effect of treating human dental pulp cells with the pharmaceutical composition according to an embodiment of the present invention on the expression of genes related to inflammatory factors under an inflammatory environment.

[0091] Figure 4 The chart is a cell experiment simulating the situation when the dental pulp inflammation is caused by caries corresponding to stage 4, and shows the effect on the survival rate of human dental pulp cells when the pharmaceutical composition according to the embodiment of the present invention is treated on the human dental pulp cells under the inflammatory environment.

[0092] Figure 5 The cell experiment simulates the situation when the dental pulp inflammation is caused by caries corresponding to stage 4, and shows the effect on the recovery of the dental pulp cells when the damaged human dental pulp cells are treated with the pharmaceutical composition according to the embodiment of the present invention under the inflammatory environment.

[0093] Figure 6 The results were obtained by conducting a cell experiment simulating the situation when pulp inflammation caused by caries corresponding to stage 4 was caused, and observing the effect on the mineralization ability of human pulp cells. DETAILED DESCRIPTION

[0094] The purpose and effect of the present invention and the technical structure for achieving the same will be clear if the embodiments described in detail below together with the accompanying drawings are referred to. In describing the present invention, when it is judged that the detailed description of a known function or structure may unnecessarily confuse the gist of the present invention, the detailed description will be omitted. Moreover, the terms described below, as terms defined in consideration of the functions in the present invention, may vary according to the intention or convention of the user or operator.

[0095] However, the present invention is not limited to the embodiments disclosed below, and can be embodied in various forms that are different from each other. However, this embodiment is provided to make the disclosure of the present invention more complete and to fully explain the scope of the invention to people with ordinary knowledge in the technical field to which the present invention belongs, and the present invention is only defined by the scope of the claims. Therefore, this definition should be made based on the entire content of this specification.

[0096] The present invention is described in more detail below by way of examples, but these examples are only used to illustrate the present invention by way of example, rather than to limit the scope of the present invention by these examples.

[0097] Example 1: Synthesis of peptides

[0098] The present inventors synthesized a peptide (sequence number 1) showing a regeneration-promoting effect on dentin or pulp tissue by the 9-fluorenylmethyloxycarbonyl (Fmoc) method, and substituted amino acids of the synthesized peptide to synthesize peptides of various groups (Tables 1 to 12).

[0099] N-KYQRRKKNKY-C (SEQ ID NO. 1)

[0100] First, the peptide of Group 1 is the peptide of Sequence No. 1, or is synthesized by substituting lysine or arginine for amino acids 5 to 7 of the peptide of Sequence No. 1 (Table 1).

[0101]

Table 1

[0102] Group 1 peptides

[0103]

[0104] Then, the amino acids at positions 5 to 7 of the peptide of SEQ ID NO: 1 were substituted with lysine or arginine, and the amino acid at position 8 was substituted with serine, thereby synthesizing peptides of Group 2 (Table 2).

[0105]

Table 2

[0106] Group 2 peptides

[0107]

[0108] Then, the amino acids at positions 5 to 7 of the peptide of SEQ ID NO: 1 were substituted with lysine or arginine, and the amino acid at position 9 was substituted with tyrosine, thereby synthesizing peptides of Group 3 (Table 3).

[0109]

Table 3

[0110] Group 3 peptides

[0111]

[0112] Then, the amino acids at positions 5 to 7 of the peptide of sequence number 1 were replaced with lysine or arginine, the amino acid at position 8 was replaced with serine, the amino acid at position 9 was replaced with tyrosine, and the amino acid at position 10 was replaced with lysine, thereby synthesizing peptides of group 4 (Table 4).

[0113]

Table 4

[0114] Group 4 peptides

[0115]

[0116] Then, the amino acid at position 3 of the peptide of sequence number 1 was substituted with arginine, the amino acid at position 4 was substituted with glutamine, and the amino acids at positions 5 to 7 were substituted with lysine or arginine, thereby synthesizing peptides of group 5 (Table 5).

[0117]

Table 5

[0118] Group 5 peptides

[0119]

[0120] Then, the amino acid at position 3 of the peptide of sequence number 1 was replaced with arginine, the amino acid at position 4 was replaced with glutamine, the amino acids at positions 5 to 7 were replaced with lysine or arginine, and the amino acid at position 8 was replaced with serine, thereby synthesizing peptides of group 6 (Table 6).

[0121]

Table 6

[0122] Group 6 peptides

[0123]

[0124]

[0125] Then, the amino acid at position 3 of the peptide of sequence number 1 was replaced by arginine, the amino acid at position 4 was replaced by glutamine, the amino acids at positions 5 to 7 were replaced by lysine or arginine, the amino acid at position 9 was replaced by tyrosine, and the amino acid at position 10 was replaced by lysine, thereby synthesizing peptides of group 7 (Table 7).

[0126]

Table 7

[0127] Group 7 peptides

[0128]

[0129] Then, the amino acid at position 3 of the peptide of sequence number 1 was replaced by arginine, the amino acid at position 4 was replaced by glutamine, the amino acids at positions 5 to 7 were replaced by lysine or arginine, the amino acid at position 8 was replaced by serine, the amino acid at position 9 was replaced by tyrosine, and the amino acid at position 10 was replaced by lysine, thereby synthesizing peptides of group 8 (Table 8).

[0130]

Table 8

[0131] Group 8 peptides

[0132]

[0133] Then, the amino acid at position 3 of the peptide of sequence number 1 was substituted with lysine, the amino acid at position 4 was substituted with glutamine, and the amino acids at positions 5 to 7 were substituted with lysine or arginine, thereby synthesizing peptides of group 9 (Table 9).

[0134]

Table 9

[0135] Group 9 peptides

[0136]

[0137] Then, the amino acid at position 3 of the peptide of sequence number 1 was replaced by lysine, the amino acid at position 4 was replaced by glutamine, the amino acids at positions 5 to 7 were replaced by lysine or arginine, and the amino acid at position 8 was replaced by serine, thereby synthesizing peptides of group 10 (Table 10).

[0138]

Table 10

[0139] Group 10 peptides

[0140]

[0141] Then, the amino acid at position 3 of the peptide of sequence number 1 was replaced by lysine, the amino acid at position 4 was replaced by glutamine, the amino acids at positions 5 to 7 were replaced by lysine or arginine, the amino acid at position 9 was replaced by tyrosine, and the amino acid at position 10 was replaced by lysine, thereby synthesizing peptides of group 11 (Table 11).

[0142]

Table 11

[0143] Group 11 peptides

[0144]

[0145]

[0146] Finally, the amino acid at position 3 of the peptide of sequence number 1 was replaced by lysine, the amino acid at position 4 was replaced by glutamine, the amino acids at positions 5 to 7 were replaced by lysine or arginine, the amino acid at position 8 was replaced by serine, the amino acid at position 9 was replaced by tyrosine, and the amino acid at position 10 was replaced by lysine, thereby synthesizing peptides of group 12 (Table 12).

[0147]

Table 12

[0148] Group 12 peptides

[0149]

[0150] Example 2: Preparation of pharmaceutical composition

[0151] The preparation method of the pharmaceutical composition (KH002) according to an embodiment of the present invention is as follows. The pharmaceutical composition (KH002) was prepared by mixing with about 1.5% carboxymethyl cellulose (Carboxymethyl cellulose, Sigma-Aldrich, C5678). Carboxymethyl cellulose (Carboxymethyl cellulose, Sigma-Aldrich, C5678) was mixed with distilled water at about 3%, boiled at 100°C, and sterilized under pressure to prepare a final concentration of about 1.5% when mixed with the peptide (KH001) of sequence number 96 among the peptides prepared according to Example 1.

[0152] Example 3: Permeability and stability of pharmaceutical compositions in a caries environment

[0153] Example 3-1: Permeability of a pharmaceutical composition in a caries environment

[0154] A pharmaceutical composition (KH002) containing a peptide (KH001) bound to a fluorescent pigment, rhodamine, was applied to extracted teeth of a person suffering from dentine caries (caries stage 2-3), and fixed with 4% paraformaldehyde after one minute. Then, the teeth were cut into sections with a thickness of about 0.1 mm in the sagittal direction using a digital low-speed diamond cutter, and observed under a confocal microscope ( Figure 1a ).

[0155] pass Figure 1a The red dyeing was observed, and it was confirmed that the peptide (KH001) contained in the pharmaceutical composition according to Example 2 effectively penetrated the caries-affected dentin and reached the dental pulp.

[0156] Example 3-2: Stability analysis of pharmaceutical composition under dental environment

[0157] 1. Stability Analysis of the Peptide in the Pharmaceutical Composition Provided in Example 2

[0158] The standard strain Streptococcus mutans (S. mutans, KCOM1054) used in this experiment was purchased from the Korean Collection of Oral Microbiology (KCOM). Mitis salivarius bacitracin (MSB; bacitracin concentration of 0.5 μg / ml) containing about 20% sucrose was spread on an agar plate medium, cultured in a candle jar at about 37°C for about 48 hours, and a single colony was cultured in a Tryptic Soy Broth (TSB; BDDIFCO, USA) culture medium for about 24 hours and used in the experiment. The Streptococcus mutans (S. mutans) strain was cultured until the absorbance (OD600) value was 1.0, and 100 ul of the cultured strain and 1.5% carboxymethyl cellulose were mixed with 100 ug of the pharmaceutical composition (KH002), and MALDI-TOF analysis (UltraflexⅢTOF / TOF (Bruker Daltonics)) was performed to analyze the stability of the peptide (KH001) contained in the pharmaceutical composition (KH002) according to the reaction time with the strain.

[0159] 2. The composition of item 1 was obtained at intervals of 1 minute, 5 minutes, 15 minutes, and 30 minutes, and centrifuged at about 15,000 rpm for about 10 minutes and the supernatant was recovered.

[0160] 3. Mix 2ul of each supernatant recovered in item 2 with 2ul of matrix solution (10mg / mL of α-cyano-4-hydroxycinnamic acid (CHCA) added to 0.1% TFA / CAN) (1:1, v / v) and perform MALDI-TOF analysis (UltraflexⅢTOF / TOF (Bruker Daltonics)) Figure 1b )

[0161] pass Figure 1b It was confirmed that the peptide (KH001) in the pharmaceutical composition (KH002) provided in Example 2 was stable in the environment of S. mutans, which is a dental caries pathogen.

[0162] Example 4: Analysis of treatment results of pharmaceutical compositions according to different dental caries stages

[0163] Example 4-1: Preparation of rat models according to various stages of dental caries

[0164] exist Figure 2a In the rat model of caries, the stages of dentine caries were divided into early, moderate, and advanced based on 1 / 3 of the dentine thickness, and the situation where the dentine above the pulp was completely carious until the pulp was eroded was classified as the most serious severe stage (Severe) and prepared separately (n=4). With such a classification, in the stages of human caries, the early stage is similar to the second stage of caries, the moderate and advanced stages are similar to the third stage of caries, and the severe stage is similar to the fourth stage of caries.

[0165] Example 4-2: Observation of treatment results of the pharmaceutical composition according to each rat model

[0166] The control group was a group suffering from caries but not coated with the pharmaceutical composition (KH002) prepared according to Example 2. The following tissue photographs were taken at the early, mid-autumn, late, and severe stages. 3 ug of the pharmaceutical composition (KH002) was coated on each tooth and the rats were sacrificed 4 weeks later. After fixation and decalcification, tissue slides were prepared for hematoxylin and eosin staining.

[0167] In the control group not treated with the pharmaceutical composition (KH002) prepared according to Example 2, liquefaction necrosis was observed inside the dental pulp, and palisade damage of odontoblasts was observed below the caries-affected part, and inflammatory cells also spread into the dental pulp. In addition, in the group treated with the pharmaceutical composition (KH002), odontoblasts below the caries-affected part all showed palisade state, and astrocytes, which are characteristic of healthy dental pulp, were observed throughout the dental pulp at the early and middle stages. Even in the severe state where the dentin above the dental pulp was caries-affected, healthy dental pulp was confirmed to be maintained at the root of the tooth.

[0168] When the pharmaceutical composition (KH002) was treated, dentin regeneration was observed in all stages of caries, and in a tooth model in a severe state, a dentin bridge was observed to be formed above the preserved pulp, which is one of the defenses against caries.

[0169] Example 4-3: Observation of inflammatory cells based on dental caries

[0170] The number of whole pulp cells and the number of inflammatory cells were compared in percentage (n=4 based on the number of individuals, n=6 based on the number of teeth). Three random sites inside the pulp were read by three researchers, and a blind method was implemented for accurate reading.

[0171] Figure 2a The results of treating the pharmaceutical composition according to the embodiment of the present invention in the dental caries rat model according to the stages of various dental caries are shown in FIG. Figure 2a It was confirmed that the ratio of ED1-stained inflammatory cells in the experimental group treated with the pharmaceutical composition (KH002) was significantly reduced compared to the control group not treated with the pharmaceutical composition (KH002). Based on this result, it can be predicted that the treatment with the pharmaceutical composition (KH002) can effectively restore inflammation caused by dental caries.

[0172] Figure 2b As a result of treating the pharmaceutical composition (KH002) in a rat caries model with a depth corresponding to stage 3 of human caries, the number of inflammatory cells diffused into the dental pulp was confirmed, and the degree of inflammation of caries was quantified by comparing ED1, a representative dental pulp inflammatory cell marker, by immunostaining chemical method.

[0173] Example 5: Analysis of the effect of the expression of inflammatory factors on dental caries

[0174] In order to confirm the preventive and therapeutic effects of the pharmaceutical composition (KH002) in the 4th stage of caries that causes inflammation after the onset of caries, the expression of inflammatory factors was compared after human dental pulp cells were treated with lipopolysaccharide (LPS (Lipopolysaccharide)) and the pharmaceutical composition (KH002).

[0175] All experiments using human dental pulp cells were approved by the Institutional Review Board (IRB; S-D20140007) of the Seoul National University Dental Hospital and were conducted in accordance with the guidelines and regulations of the agency. The third molar (wisdom tooth) was extracted from a patient who gave written consent at the Seoul National University Dental Hospital and dental pulp cells were isolated using a previously reported method (Choung et al., 2016). The tooth was cut and the internal pulp was separated with forceps, and the pulp tissue was minced into a 60-mm diameter cell culture dish. The minced pulp tissue was then covered with a coverslip and cultured in a cell culture medium to isolate human dental pulp cells. Human dental pulp cells were plated in a 6-well dish at 1×10 5 After inoculating cells in the culture dish, the negative control group was treated only in the culture dish, and the positive control group was treated only with 10μg / mL lipopolysaccharide (LPS) and 10μg / mL pharmaceutical composition (KH002), respectively. As the experimental group, in order to confirm the preventive effect, 10μg / mL lipopolysaccharide (LPS) and 10μg / mL pharmaceutical composition (KH002) were treated at the same time. In the case of the experimental group, in order to confirm the therapeutic effect, lipopolysaccharide (LPS) was treated for 24 hours and then the pharmaceutical composition (KH002) was treated.

[0176] To compare the expression of inflammatory factors, RT-PCR was performed, and to quantitatively compare the expression levels of each factor, the ratio of the expression level to GAPDH was determined ( Figure 3 ).

[0177] When human dental pulp cells were treated with lipopolysaccharide (LPS) alone, the expression of inflammatory factors such as TNF-α, IL-1α, IL-1β, IL-6, CXCL10, iNOS, and COX2 was significantly increased. In contrast, when lipopolysaccharide (LPS) was treated first and then the pharmaceutical composition (KH002) was applied, and when lipopolysaccharide (LPS) and the pharmaceutical composition (KH002) were treated simultaneously, it was confirmed that the expression status was similar to that of the negative control group without any treatment. This result shows that when inflammation is caused after suffering from dental caries, the pharmaceutical composition (KH002) has a relieving effect on the prevention and treatment of dental caries-related inflammation.

[0178] The primer sequences for RT-PCR of each factor are as follows (Table 13).

[0179]

Table 13

[0180]

[0181]

[0182] Example 6: Analysis of the effect on the survival rate of dental pulp cells

[0183] The effect of a pharmaceutical composition (KH002) on the cell survival rate of human dental pulp cells in an inflammatory environment was confirmed in relation to stage 4 caries that causes inflammation after the onset of caries.

[0184] To measure cell viability, human dental pulp cells were plated in 96-well plates at 5 × 10 3 After the cells were seeded at 1440 cells / well, 150 μL of MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-tetrazolium bromide solution, Medifab) was treated for about 2 hours on the 1st, 3rd, and 5th days, and the absorbance of the solution dissolved in DMSO was measured at 570 nm.

[0185] All experiments using human dental pulp cells were approved by the Institutional Review Board (IRB; S-D20140007) of the Seoul National University Dental Hospital and were conducted in accordance with the guidelines and regulations of the agency. The third molar (wisdom tooth) was extracted from a patient who gave written consent at the Seoul National University Dental Hospital and dental pulp cells were isolated using a previously reported method (Choung et al., 2016). The tooth was cut and the internal pulp was separated with forceps, and the pulp tissue was minced into a 60-mm diameter cell culture dish. The minced pulp tissue was then covered with a coverslip and cultured in a cell culture medium to isolate human dental pulp cells. Human dental pulp cells were plated in a 6-well dish at 1×10 5 After inoculating cells in the culture dish, the negative control group was treated only in the culture dish, and the positive control group was treated only with 10μg / mL lipopolysaccharide (LPS) and 10μg / mL pharmaceutical composition (KH002), respectively. As the experimental group, in order to confirm the preventive effect, 10μg / mL lipopolysaccharide (LPS) and 10μg / mL pharmaceutical composition (KH002) were treated at the same time. In the case of the experimental group, in order to confirm the therapeutic effect, lipopolysaccharide (LPS) was treated for 24 hours and then the pharmaceutical composition (KH002) was treated.

[0186] Figure 4 This graph shows the effect of treating human dental pulp cells with a pharmaceutical composition (KH002) on the survival rate of dental pulp cells under an inflammatory environment in a cell experiment simulating the situation when dental pulp inflammation occurs due to caries corresponding to stage 4.

[0187] The experimental group treated with the pharmaceutical composition (KH002) at a concentration of 10 μg / mL did not show a large difference from the negative control group. The group treated with 10 μg / mL of lipopolysaccharide (LPS) showed a significant decrease in the survival rate of dental pulp cells compared to the negative control group, while the survival rate of dental pulp cells in the group treated with 10 μg / mL of lipopolysaccharide (LPS) and 10 μg / mL of the pharmaceutical composition (KH002) was restored to a level similar to that of the negative control group.

[0188] Such results suggest that the pharmaceutical composition (KH002) can provide the function of protecting the dental pulp and alleviating inflammation by increasing the survival rate of human dental pulp cells when inflammation is caused by dental caries.

[0189] Example 7: Analysis of the effect on the recovery of dental pulp cells

[0190] The effects of the pharmaceutical composition (KH002) on wound healing ability in a human dental pulp cell wound healing model under an inflammatory environment were confirmed.

[0191] Human dental pulp cells were cultured in 6-well plates at 1 × 10 5 After inoculation of 10 cells / well, the next day the central part was scraped with a 200 uL pipette tip and the cell growth rate was compared 24 hours later.

[0192] All experiments using human dental pulp cells were approved by the Institutional Review Board (IRB; S-D20140007) of the Seoul National University Dental Hospital and were conducted in accordance with the guidelines and regulations of the agency. The third molar (wisdom tooth) was extracted from a patient who gave written consent at the Seoul National University Dental Hospital and dental pulp cells were isolated using a previously reported method (Choung et al., 2016). The tooth was cut and the internal pulp was separated with forceps, and the pulp tissue was minced into a 60-mm diameter cell culture dish. The minced pulp tissue was then covered with a coverslip and cultured in a cell culture medium to isolate human dental pulp cells. Human dental pulp cells were plated in a 6-well dish at 1×10 5 After the cells were inoculated at 10 μg / mL per well, the negative control group was treated only in the culture dish, and the positive control group was treated only with 10 μg / mL of lipopolysaccharide (LPS) and 10 μg / mL of the pharmaceutical composition (KH002). As the experimental group, in order to confirm the preventive effect, 10 μg / mL of lipopolysaccharide (LPS) and 10 μg / mL of the pharmaceutical composition (KH002) were treated at the same time. In the case of the experimental group, in order to confirm the effect on the recovery of dental pulp cells, lipopolysaccharide (LPS) was treated for 24 hours and then the pharmaceutical composition (KH002) was treated.

[0193] The cells were photographed using an optical microscope with a 10x objective lens, and the photographs were analyzed using the ImageJ program.

[0194] Figure 5 The results of a cell experiment simulating the situation of pulp inflammation caused by caries corresponding to stage 4 show the effect of treating damaged human pulp cells with the pharmaceutical composition according to an embodiment of the present invention on the recovery of pulp cells under an inflammatory environment.

[0195] The wound healing ability of the experimental group was quantified as a ratio to the control group. The group treated with the pharmaceutical composition (KH002) alone had no significant difference from the control group, but the wound healing ability of the group treated with lipopolysaccharide (LPS) was significantly reduced to about 50% of the control group. In the group treated with lipopolysaccharide (LPS) and the pharmaceutical composition (KH002), the wound healing ability was restored to about 90%, so it was confirmed that the pharmaceutical composition (KH002) can also restore the wound healing ability of human dental pulp cells under the inflammatory environment caused by dental caries.

[0196] Example 8: Analysis of the effect on the mineralization ability of dental pulp cells

[0197] The effect of treatment with a pharmaceutical composition (KH002) on the mineralization ability of human dental pulp cells when inflammation is induced after dental caries was confirmed.

[0198] To this end, human dental pulp cells were cultured in 6-well dishes at 1 × 10 5 After seeding at 10 cells / well, the cells were cultured in a differentiation medium containing ascorbic acid (50 μg / mL) and β-glycerophosphate (10 mM) for 7, 14, and 21 days starting from the next day.

[0199] All experiments using human dental pulp cells were approved by the Institutional Review Board (IRB; S-D20140007) of the Seoul National University Dental Hospital and were conducted in accordance with the guidelines and regulations of the agency. The third molar (wisdom tooth) was extracted from a patient who gave written consent at the Seoul National University Dental Hospital and dental pulp cells were isolated using a previously reported method (Choung et al., 2016). The tooth was cut and the internal pulp was separated with forceps, and the pulp tissue was minced into a 60-mm diameter cell culture dish. The minced pulp tissue was then covered with a coverslip and cultured in a cell culture medium to isolate human dental pulp cells. Human dental pulp cells were plated in a 6-well dish at 1×10 5 After inoculating cells at 10 μg / mL, the negative control group was treated only in the culture dish, and the positive control group was treated only with 10 μg / mL of lipopolysaccharide (LPS) and 10 μg / mL of the pharmaceutical composition (KH002). As the experimental group, in order to confirm the preventive effect, 10 μg / mL of lipopolysaccharide (LPS) and 10 μg / mL of the pharmaceutical composition (KH002) were treated at the same time. In the case of the experimental group, in order to confirm the effect on mineralization ability, lipopolysaccharide (LPS) was treated for 24 hours and then the pharmaceutical composition (KH002) was treated.

[0200] To compare the amount of mineralized matrix, after fixation with 4% PFA at 4°C overnight, 40 mM alizarin red S adjusted to pH 4.2 was treated at 25°C for 30 minutes. Then, 0.5 mL of sodium dodecyl sulfate dissolved in 0.5N hydrochloric acid was applied, and after shaking for 30 minutes, the absorbance was measured at 405 nm.

[0201] Figure 6 The results of this study were obtained by simulating the conditions of pulp inflammation caused by caries corresponding to the 4th stage, and observing the effects on the mineralization capacity of human pulp cells. Figure 6Compared with the control group, the size of the mineral nodules on the 21st day increased in the group treated with the pharmaceutical composition (KH002), and the amount of the mineralized matrix on the 7th, 14th, and 21st days also increased significantly. In contrast, in the group treated with lipopolysaccharide (LPS), the size of the mineral nodules on the 21st day and the amount of the mineralized matrix on the 7th, 14th, and 21st days decreased significantly compared with the control group. Compared with the group treated with lipopolysaccharide (LPS), the size of the mineral nodules on the 21st day increased in the group treated with lipopolysaccharide (LPS) and the pharmaceutical composition (KH002), and the amount of the mineralized matrix recovered to a level almost similar to that of the negative control group on the 7th and 14th days. In the case of the experimental group, after 21 days, although it did not recover to the same level as the control group, it showed a statistically significant increase compared with the group treated with only lipopolysaccharide (LPS). These results confirmed that the pharmaceutical composition (KH002) can restore and enhance the dentin secretion ability of odontoblasts in human dental pulp cells under an inflammatory environment caused by caries, thereby providing an effect of restoring the thickness of damaged dentin.

[0202] The pharmaceutical composition according to the embodiments of the present invention can prevent or cure root caries in the elderly that is difficult to treat with conventional caries treatment methods, maintain young teeth with caries in children and adolescents until they fall out, and can be used for the prevention and treatment of various caries diseases.

[0203] Moreover, in the case of the pharmaceutical composition according to the embodiments of the present invention, in the case of severe caries stages, when inflammation is caused that cannot be restored to the natural tooth state by conventional caries treatment, it can also protect odontoblasts and provide autophagy of newly formed odontoblasts, thereby providing the effect of treating caries by protecting dental pulp cells.

[0204] The preferred embodiments of the present invention are disclosed in this specification and the drawings. Although specific terms are used, they are used in a general sense only to easily explain the technical content of the present invention and to facilitate understanding of the invention, and are not used to limit the scope of the present invention. In addition to the embodiments disclosed herein, other variations based on the technical ideas of the present invention may also be implemented, which is obvious to a person with ordinary knowledge in the technical field to which the present invention belongs.

Claims

1. A pharmaceutical composition for preventing or treating dental caries, comprising as an active ingredient a peptide consisting of an amino acid sequence of the following general formula 1, wherein: KY-R1-R2-R3-R4-R5-R6-R7-R8 (Formula 1) In the general formula 1, R1 is arginine (R), lysine (K) or glutamine (Q); R2 is arginine (R) or glutamine (Q); R3, R4 and R5 are arginine (R) or lysine (K), respectively; R6 is asparagine (N) or serine (S); and R7 and R8 are lysine (K) or tyrosine (Y).

2. The pharmaceutical composition for preventing or treating dental caries according to claim 1, characterized in that: The peptide is composed of any one of the amino acid sequences in sequence numbers 1 to 96.

3. The pharmaceutical composition for preventing or treating dental caries according to claim 1, characterized in that: The pharmaceutical composition comprises a polypeptide to which the peptides are repeatedly linked.

4. The pharmaceutical composition for preventing or treating dental caries according to claim 1, characterized in that: The pharmaceutical composition comprises a complex of a drug having an antibacterial effect on oral bacteria and the peptide.

5. The pharmaceutical composition for preventing or treating dental caries according to claim 1, characterized in that: The pharmaceutical composition further comprises a pharmaceutically acceptable carrier, excipient or diluent.

6. A quasi-drug composition for preventing or improving dental caries, comprising the peptide according to claim 1 or 2.

7. A health functional food composition for preventing or improving dental caries, comprising the peptide according to claim 1 or 2.

8. A method for preventing or treating dental caries, comprising treating an individual other than a human with a pharmaceutical composition for preventing or treating dental caries, wherein: As an active ingredient, it contains a peptide consisting of an amino acid sequence of the following general formula 1, KY-R1-R2-R3-R4-R5-R6-R7-R8 (Formula 1) In the general formula 1, R1 is arginine (R), lysine (K) or glutamine (Q); R2 is arginine (R) or glutamine (Q); R3, R4 and R5 are arginine (R) or lysine (K), respectively; R6 is asparagine (N) or serine (S); and R7 and R8 are lysine (K) or tyrosine (Y).